Professionals 231 Users Online

Prosthetic Joint Infection Treatment Market

Market Study on Prosthetic Joint Infection Treatment: Post-operative Infections Major Cause of Concern

Prosthetic Joint Infection Treatment Market Segmented By Treatment in Debridement, Antibiotics, Irrigation with Implant Retention with Distributional Channel in Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers

Prosthetic Joint Infection Treatment Market Outlook (2023 to 2033)

The global prosthetic joint infection treatment market is predicted to expand at a CAGR of 4.9% from 2023 to 2033. In 2022, the market stood at US$ 100.4 million and is thus expected to reach US$ 170 million by 2033-end.

Prosthetic joint infections (PJIs) require effective therapeutic strategies like debridement, antibiotics, and irrigation with implant retention (DAIR) therapy due to their complex nature. PJIs can be caused by various factors such as surgical site contamination, hematogenous spread of bacteria, or direct introduction during implant surgery. It occurs when bacteria form a biofilm on the implant surface, making them resistant to immune response and antibiotics.

DAIR is crucial as it offers simplicity, shorter recovery time, and improved quality of life. While treatable, its success depends on factors like the type of pathogen, antibiotic sensitivity, and early intervention, highlighting the need for innovative approaches in PJI management.

  • By drug type, glycopeptides accounted for a market share of 34.8% in 2022.
  • Revenue from sales of prosthetic joint infection treatment solutions accounted for 6.8% share of the global surgical site infection control market in 2022, which was valued at US$ 1.48 billion.

Since biofilms are highly organized communities of microbial cells with various phenotypes, the microbial biofilm paradigm is essential to comprehending DAIR for PJI therapy. Understanding biofilm formation can help develop targeted therapies, combination therapies, and preventive strategies. Combining antibiotics, antimicrobial agents, and biofilm-disrupting agents can increase treatment efficacy.

PJIs are a growing concern in orthopedics, especially with the increasing number of total hip and knee arthroplasty procedures. PJI leads to higher hospital readmissions, patient mortality, and substantial treatment costs, up to four times the cost of primary implantation.

  • As per the National Institutes of Health 2019, the projected three-fold increase in PJI cases by 2030 highlights the need for urgent action.

Risk factors include revision arthroscopy, prior infection, smoking, obesity, rheumatoid arthritis, cancer, immunosuppression, and diabetes mellitus. PJI diagnosis is challenging due to pathogenic bacteria's virulence and varying patient responses. Treatment for joint infection symptoms typically involves multiple surgical procedures and prolonged medical therapy, resulting in a significant financial burden. Gram-negative microbes are also a worry, but if basic ideas like a short symptom duration and anti-biofilm antibiotic treatment are followed, DAIR therapy is expected to be successful in this patient population.

Attribute Details
Prosthetic Joint Infection Treatment Market Size (2022) US$ 100.4 Million
Estimated Market Value (2023) US$ 105.5 Million
Projected Market Value (2033) US$ 170 Million
Global Market Growth Rate (2023 to 2033) 4.9% CAGR
Market Share of Top 5 Countries (2022) 53.1%
Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

What’s Influencing the Demand Growth for PJI Treatment?

“Growing Emphasis on Employing DAIR Procedures and Multidisciplinary Collaboration”

Demand for PJI treatments is being driven by several key factors that highlight the importance of effective therapeutic strategies. One significant approach gaining attention is DAIR. This method offers simplicity, shorter recovery time, and reduced physiological damage. Research shows that successful DAIR procedures result in functional outcomes and improved quality of life comparable to uninfected cases. Several variables influence the success of implant retention surgery DAIR, including method, antibiotic regimen, host health, and pathogen type.

Biofilms are organized microbial communities with phenotypic variations, fostering bacteria growth resistant to the host immune system and drugs. These biofilms can form on the implanted joint prosthesis, leading to persistent infections that are difficult to treat. This underscores the significance of finding innovative and effective treatment strategies to combat prosthetic joint infections caused by biofilm-forming bacteria.

Achieving success with gram-negative infections using DAIR involves early intervention and anti-biofilm antibiotic treatment. The broader scenario underscores the demand for innovative strategies in PJI treatments. PJI is a critical healthcare issue that necessitates the collaboration of a multidisciplinary team of microbiologists, infectious disease experts, rheumatologists, and orthopedics.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What are the Main Challenges Faced by Prosthetic Joint Infection Treatment Providers?

“Limited Success of DAIR Therapy and Antibiotic Resistance Affecting Treatment Outcomes”

Demand for prosthetic joint management and PJI treatment faces significant obstacles. DAIR procedures are simpler and less physiologically harmful, but their success can be limited. Patients who experience failed DAIR often require additional surgeries, leading to increased morbidity and costs. Studies suggest that a two-stage exchange after an unsuccessful DAIR may yield poor outcomes, highlighting the need for caution.

Despite DAIR's potential, outcomes can be affected by factors such as the infecting microorganism's sensitivity to antibiotics. For instance, Methicillin-resistant S. aureus (MRSA) infections often yield poor DAIR outcomes. Gram-negative microbes also pose challenges, particularly due to antibiotic resistance.

The microbial biofilm paradigm, which involves organized microbial communities with drug-resistant properties, is crucial in understanding DAIR for PJI. Biofilms generate matrices supporting bacteria growth, resisting immune response and treatment. Variables like the method, antibiotic regimen, host condition, and pathogen affect DAIR outcomes. Exchange arthroplasty has a higher chance of success than debridement alone, although methicillin resistance has little effect on how quickly wounds heal.

  • As per Open Forum Infectious Diseases, only 55% to 69% of S. aureus infections were successfully treated with DAIR in 2021.

Despite these PJI prevention challenges, applying anti-biofilm antibiotic treatment and considering factors like symptom duration can enhance DAIR success rates. Addressing antibiotic resistance is pivotal for effective PJI management.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Country-wise Insights

What is the Contributing Factor Behind the Growth of the United States Market?

“High Prevalence of Healthcare-associated Infections”

The United States accounted for 23.2% share of the global prosthetic joint infection treatment market in 2022.

Growing demand for PJI treatment in the United States can be attributed to healthcare-associated infections (HCAIs) that develop during medical care. HCAIs occur in healthcare facilities after 48 hours of admission or within 30 days of receiving care.

  • As per an Infection and Drug Resistance study (2018), with around 1.7 million patients acquiring HCAIs annually in the United States and over 98,000 patients succumbing to them, the significance of infection control is evident.

Simple measures such as hand hygiene can prevent HCAIs, reducing morbidity, mortality, and healthcare costs. Recognizing the impact of HCAIs, efforts to promote infection control through guidelines and education, including the WHO's hand-washing initiatives, are vital to address the demand for effective PJI treatment. These factors are responsible for market growth in the United States.

How is the PJI Treatment Market Shaping Up in India?

“Growing Medical Tourism Driven by Availability of Skilled Healthcare Professionals”

India held 9.2% share of the global market in the year 2022. Growing demand for PJI treatment in India is intertwined with the remarkable growth of its healthcare sector.

  • Driven by factors like medical tourism, the Indian healthcare industry has witnessed significant growth, projected to reach an approximate value of US$ 133.44 billion by 2020, as stated in the International Journal of Global Business and Competitiveness, 2022.

India's medical tourism sector offers competitive pricing, skilled medical professionals, high-quality care, and a diverse array of treatments. India is becoming a hub for medical travel, attracting patients from across the globe for procedures ranging from cardiology to cosmetics.

Government initiatives, like the National Medical & Wellness Tourism Promotion Board, further amplify India's appeal as a medical travel destination.

What are the Demand Projections for PJI Treatment in China?

“Rising Number of Joint Replacement Surgeries”

China accounted for 8.6% share of the global market in 2022. Demand for PJI treatment in the country is growing due to the expanding patient pool requiring artificial joint replacement procedures.

  • Total hip arthroplasty (THA) and total knee arthroplasty (TKA) cases increased by 2.4-fold and 5.9-fold respectively, with more preference for domestic implants, according to the Chinese Medical Journal, 2020. Despite the absence of a national joint registration system, this study underscores China's increasing adoption of joint replacements, potentially reaching around 0.9 million cases in 2019.

PJIs pose a significant therapeutic challenge as being a complication post total joint arthroplasty (TJA) and lead to an increased socioeconomic burden on the Chinese healthcare system. This is predicted to drive the demand for PJI treatment solutions in China during the forecast period.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Category-wise Insights

Which Pharmaceutical Agent is Widely Utilized for Treating PJIs?

“Extensive Use of Glycopeptides Due to Their Ability to Target Resistant Strains”

By drug, glycopeptides are most widely used for PJI treatment and occupied 33.9% share of the global market in 2022.

Glycopeptides are antibiotics, including vancomycin and teicoplanin, essential in managing severe bacterial infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci.

Due to their potent bactericidal effects and coverage against a range of pathogens, glycopeptides are often used as first-line therapies or in combination with other antibiotics for PJI. Their ability to target resistant strains and provide effective treatment makes them a crucial choice in addressing the challenging infections associated with prosthetic joint replacements, ensuring improved patient outcomes and reduced risk of complications.

Which Type of Infection is Widely Prevalent and Requires Treatment?

“High Demand for Post-operative Infection Treatment Due to Complexity of Condition”

By infection, post-operative infections accounted for 78.7% share of the global market in 2022. Post-operative infections can result in issues such as inflammation and discomfort surrounding the prosthetic joint.

Post-operative infections frequently need specialist care, such as antibiotics and, in severe situations, surgery to remove the infected implant. The complexity and severity of post-operative infections fuel the demand for innovative and effective treatment solutions, leading to high revenue generation for market players.

What’s Contributing to Staphylococcus Aureus Generating Significant Revenue?

“Aggressive Nature and Ubiquity of Staphylococcus Aureus Necessitating Specialist Therapies”

By pathogen type, Staphylococcus aureus accounted for 35.8% share of the global market in 2022.

Early infections, occurring during the first four weeks following the initial surgery, are typically caused by Staphylococcus aureus due to its aggressive nature and ubiquity in generating infections. This pathogen is known to develop biofilms, making infections difficult to treat and recurring.

Staphylococcus aureus is the most common pathogen, accounting for more than half of all prosthetic joint failures and infections. The sluggish development of tiny colony forms of Staphylococcus aureus adds to the difficulty of these infections. Effective treatment options for Staphylococcus aureus and associated biofilm are critical, fueling demand for specialist therapies and generating significant income.

What Makes the Intravenous Route a Widely Preferred Method of Treatment?

“Direct Bloodstream Delivery through Intravenous Route Leads to Enhanced Antibiotic Efficacy”

The intravenous administration route accounted for 67.6% share of the global market in 2022 due to its direct and rapid delivery of antibiotics into the bloodstream. Intravenous antibiotics ensure effective and targeted treatment, reaching the infection site directly. This route is preferred for severe cases of prosthetic joint infections, ensuring higher concentrations of antibiotics are delivered quickly to combat the infection.

Intravenous administration also allows for close monitoring and adjustment of the treatment regimen, contributing to better patient outcomes. Demand for intravenous antibiotics for prosthetic joint infections is driving revenue growth in the market, as healthcare providers prioritize efficient and impactful treatment options.

Competition Landscape

The prosthetic joint infection treatment industry is highly fragmented, with several competitors offering products and services locally. These businesses are using strategies such as business expansion and innovation to meet patients’ demands and grow their customer base.

  • In December 2020, the University of Buffalo researchers and Garwood Medical Devices collaborated to evaluate BioPrax, a medical device that uses UB-licensed technology to prevent, control, and eliminate bacterial biofilm infections in orthopedic implants. The United States FDA has granted it a Breakthrough Device designation.
  • In June 2018, Peptilogics received FDA QIDP designation for its PLG0206 treatment for PJIs, potentially reducing inpatient costs for over 65,000 patients by 2020.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the prosthetic joint infection treatment market, which are available in the full report.

Prosthetic Joint Infection Treatment Industry Report Scope

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis US$ Million for Value
Key Countries Covered
  • United States
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • France
  • Spain
  • Russia
  • Italy
  • Benelux
  • United Kingdom
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Thailand
  • Philippines
  • Malaysia
  • Vietnam
  • Australia
  • New Zealand
  • GCC Countries
  • Türkiye
  • Egypt
  • Israel
  • South Africa
  • Northern Africa
Key Market Segments Covered
  • Drug
  • Infection
  • Route of Administration
  • Pathogen
  • Distribution Channel
  • Region
Key Companies Covered
  • Pfizer Inc.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceuticals
  • Merck & Co.
  • Eli Lilly & Company
  • AstraZeneca PLC
  • Lupin Limited
  • Dr. Reddys Laboratories
  • Aurobindo Pharma Ltd.
  • GSK PLC
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
Report Coverage
  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segments of Prosthetic Joint Infection Treatment Industry Research

By Drug:

  • Aminoglycosides
  • Glycopeptides
  • Rifamycin
  • Lincosamide
  • Penicillin
  • Other Antibiotics

By Infection:

  • Pre-operative Infection
  • Post-operative Infection

By Route of Administration:

  • Oral
  • Intravenous

By Pathogen:

  • Staphylococcus Aureus
  • Coagulase-negative Staphylococcus
  • Candida Species
  • Enterococcus Species
  • Other Pathogens

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

- Companies Covered in This Report -

  • Pfizer Inc.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceuticals
  • Merck & Co.
  • Eli Lilly & Company
  • AstraZeneca plc.
  • Lupin Limited
  • Dr Reddys Laboratories
  • Aurobindo Pharma Ltd
  • GSK plc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla ltd.

- Frequently Asked Questions -

The global prosthetic joint infection treatment market was valued at US$ 100.4 million in 2022.

Demand for prosthetic joint infection treatment increased at 5.4% CAGR from 2017 to 2022.

The United States accounted for 23.3% share of the global market in 2022.

India held 9.2% share of the global PJI treatment market in 2022.

China accounted for a valuation of US$ 8.6 million in 2022.

Glycopeptides held a leading market share of 33.9% in 2022.

The United States, India, China, Japan, and Germany together account for 53.1% market share.

Revenue from PJI treatment is projected to increase at 4.9% CAGR through 2033.

The global market for PJI treatment is set to reach US$ 170 million by the end of 2033.

Leading PJI treatment solution providers are Pfizer, Novartis, Merck & Co., and AstraZeneca.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate